11:59 AM EDT, 09/05/2024 (MT Newswires) -- Emil D Kakkis, Director, President & CEO, on September 03, 2024, sold 20,000 shares in Ultragenyx Pharmaceutical ( RARE ) for $1,117,000. Following the Form 4 filing with the SEC, Kakkis has control over a total of 2,788,582 shares of the company, with 564,597 shares held directly and 2,223,985 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1515673/000095017024103811/xslF345X05/ownership.xml

Price: 55.77, Change: -0.35, Percent Change: -0.62